AIMS: The nuclear enzyme DNA topoisomerase II has been shown to be required for chromatin condensation and chromosomal segregation during mitosis; its isoform topo II alpha is linked with active cell proliferation in mammalian cells. The aim of this study was to examine the relation of the expression of topo II alpha to the biological behaviour of conventional urinary bladder cancer. METHODS: Formalin fixed, paraffin wax embedded tissue from 94 specimens of bladder urothelial cancer were immuno-histochemically stained for topo II alpha. For each case, a topo II alpha index was determined. A similar index had been determined for Ki-67, a known cell proliferation marker. Each case had also been graded, staged, and evaluated for DNA ploidy as well as for p53 and bcl-2 immunoreactivity. RESULTS: Raised topo II alpha expression (in > or = 10% of malignant nuclei) correlated with two adverse prognosticators--high grade (p = 0.027) and invasion of the muscularis propria (p = 0.013), but with no other evaluated parameter. By multivariate survival analysis using Cox's proportional hazard model, high expression of topo II alpha was found to be predictive for worse survival (p = 0.0047). Patients' age, tumour stage, and grade were also retained as independent prognostic factors (p = 0.0349, p = 0.00005, and p = 0.0130, respectively). The negative influence of increased topo II alpha immunopositivity on patients' survival was also seen in the subgroup of patients with non-muscle invasive carcinomas (p = 0.0004), in patients with a bcl-2 negative phenotype (p = 0.0330), and in those with low Ki-67 indices (p = 0.0341). CONCLUSIONS: Because topo II alpha and Ki-67 failed to demonstrate a significant interrelation, they appear to be different molecules that both function at separate phases in the complex process of cellular proliferation. The assessment of increased topo II alpha immunoreactivity in specimens from urothelial carcinomas might help to select patients (particularly among those with superficial tumours) in the worse prognostic categories for new therapeutic strategies.
AIMS: The nuclear enzyme DNA topoisomerase II has been shown to be required for chromatin condensation and chromosomal segregation during mitosis; its isoform topo II alpha is linked with active cell proliferation in mammalian cells. The aim of this study was to examine the relation of the expression of topo II alpha to the biological behaviour of conventional urinary bladder cancer. METHODS:Formalin fixed, paraffin wax embedded tissue from 94 specimens of bladder urothelial cancer were immuno-histochemically stained for topo II alpha. For each case, a topo II alpha index was determined. A similar index had been determined for Ki-67, a known cell proliferation marker. Each case had also been graded, staged, and evaluated for DNA ploidy as well as for p53 and bcl-2 immunoreactivity. RESULTS: Raised topo II alpha expression (in > or = 10% of malignant nuclei) correlated with two adverse prognosticators--high grade (p = 0.027) and invasion of the muscularis propria (p = 0.013), but with no other evaluated parameter. By multivariate survival analysis using Cox's proportional hazard model, high expression of topo II alpha was found to be predictive for worse survival (p = 0.0047). Patients' age, tumour stage, and grade were also retained as independent prognostic factors (p = 0.0349, p = 0.00005, and p = 0.0130, respectively). The negative influence of increased topo II alpha immunopositivity on patients' survival was also seen in the subgroup of patients with non-muscle invasive carcinomas (p = 0.0004), in patients with a bcl-2 negative phenotype (p = 0.0330), and in those with low Ki-67 indices (p = 0.0341). CONCLUSIONS: Because topo II alpha and Ki-67 failed to demonstrate a significant interrelation, they appear to be different molecules that both function at separate phases in the complex process of cellular proliferation. The assessment of increased topo II alpha immunoreactivity in specimens from urothelial carcinomas might help to select patients (particularly among those with superficial tumours) in the worse prognostic categories for new therapeutic strategies.
Authors: A M Dingemans; M A Witlox; R A Stallaert; P van der Valk; P E Postmus; G Giaccone Journal: Clin Cancer Res Date: 1999-08 Impact factor: 12.531
Authors: L Nakopoulou; C Constantinides; J Papandropoulos; G Theodoropoulos; A Tzonou; A Giannopoulos; A Zervas; C Dimopoulos Journal: Urology Date: 1995-09 Impact factor: 2.649
Authors: Klaus Aumayr; Tobias Klatte; Barbara Neudert; Peter Birner; Shahrokh Shariat; Manuela Schmidinger; Martin Susani; Andrea Haitel Journal: Pathol Oncol Res Date: 2017-07-28 Impact factor: 3.201
Authors: L Nakopoulou; A C Lazaris; E G Panayotopoulou; I Giannopoulou; N Givalos; S Markaki; A Keramopoulos Journal: J Clin Pathol Date: 2004-05 Impact factor: 3.411
Authors: P Gouveris; A C Lazaris; T G Papathomas; A Nonni; V Kyriakou; J Delladetsima; E S Patsouris; N Tsavaris Journal: J Cancer Res Clin Oncol Date: 2007-06-29 Impact factor: 4.553
Authors: Marina França de Resende; Samantha Vieira; Ludmilla Thomé Domingos Chinen; Francesco Chiappelli; Francisco Paulo da Fonseca; Gustavo Cardoso Guimarães; Fernando Augusto Soares; Ivan Neves; Simone Pagotty; Peter A Pellionisz; Andre Barkhordarian; Xenia Brant; Rafael Malagoli Rocha Journal: J Transl Med Date: 2013-02-11 Impact factor: 5.531
Authors: Ali A Shamaa; Manal M Zyada; Mathias Wagner; Sally S Awad; Mohamed M Osman; Ali A Abdel Azeem Journal: Diagn Pathol Date: 2008-11-20 Impact factor: 2.644